- Centers & Specialties
- Clinical Interests
- Prostate cancer
- Kidney cancer
- Bladder cancer
- Testicular cancer
- Kidney sparing surgery
- Reconstructive surgery after bladder removal
- GU Oncology
- Medical Education
- MD, Creighton University School of Medicine
- Residency, Mayo Clinic
- Board Certifications
- Boston: Massachusetts General Hospital
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr. Michael L. Blute received his BA Degree from the College of the Holy Cross in Worcester, and his medical degree from Creighton University School of Medicine in 1982, graduating Magna Cum Laude. Subsequent to internship and residency in urology at the Mayo Clinic in Rochester, he remained on the staff and rose rapidly through the ranks to become the Anson L. Clark Professor and Chairman in the Department of Urology in 1999. He remained as Chairman of the Department of Urology and on the Executive Board of the Mayo Clinic until appointed Interim Chief of Urology and Director of the Cancer Center of Excellence at the University of Massachusetts Memorial Medical Center in 2010. In April 2012 Dr. Blute was appointed Chief of Urology at The Massachusetts General Hospital in Boston and is the Walter S. Kerr, Jr. Professor of Surgery, Harvard Medical School.
Dr. Blute has had a major interest in urologic oncology and is well-known in the field of academic urology. His major areas of interest include prostate cancer, nephron-sparing surgery for kidney masses and the management of complex renal cell and bladder neoplasms. He has been involved in phase III trials of Finasteride, chemoprevention of prostatic intraepithelial neoplasia with anti-androgens, minimally invasive surgery for BPH, biomarkers in prostate cancer, and discovery of B7 family of “Check Point Inhibitor” Biomarkers in kidney cancer.
He serves as a reviewer on 13 editorial boards. He also serves on the AUA Renal Mass Guideline Panel and the American Joint Committee on Cancer. He was the recipient of the 2010 AUA Career Contribution Award. His bibliography includes 387 peer-reviewed publications, one book and 26 book chapters.
Orthotopic neobladder reconstruction is becoming the diversion procedure of choice for female cystectomy patients due to recent advances in care for female urology patients
Complete removal of a tumor thrombus resulting from venous tumor invasion is essential for eliminating the cancer in patients with advanced renal cell carcinoma (RCC). A multispecialty tumor thrombus team within an integrated practice can improve the safety of this intricate and extensive procedure.
The MGH Department of Urology is working to increase awareness of the second leading cause of cancer death in men and other prostate related health concerns. Michael Blute answers questions about what men can do to protect themselves and their loved ones.
Michael Blute Sr., MD, has worked continuously to increase awareness of genitourinary cancer as he helps Mass General continue its leadership role in tackling urology issues.
Since the advent of targeted cancer therapies in the mid-2000s, there has been a dramatic reduction in cytoreductive nephrectomies. Dr. Michael Blute of Massachusetts General Hospital states that the reduction is concerning, since cytoreductive nephrectomy can provide a strong survival advantage to patients with metastatic disease.
Urology Graduation 2018
View a slideshow of the graduation for Urology residents held in May 2018.
165 Cambridge St
Boston, MA 02114